Immunotherapy

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in the position.

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, according to the agent’s manufacturer.

BOSTON — Managing food allergies should involve more than just allergen avoidance, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Satricabtagene autoleucel improved PFS compared with physician’s choice of therapy for patients with Claudin18.2 expression-positive advanced gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.

SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with high-risk relapsed or refractory multiple myeloma, results of the phase 2 iMMagine-1 study showed.

As 2024 comes to a close, Healio is pleased to present our most widely read oncology and hematology content from the past 12 months.

Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, has been named president-elect of ASCO and will lead the 2026 to 2027 term.

It’s only the beginning.

Laura J. van ’t Veer, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for Dec. 10-13.

Treatment with immune checkpoint inhibitors appeared linked with higher risk for venous thromboembolism among adults with metastatic lung cancer, according to study results presented at CHEST Annual Meeting.